The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05098236
Recruitment Status : Active, not recruiting
First Posted : October 28, 2021
Last Update Posted : August 18, 2023
Sponsor:
Collaborator:
National Eye Institute (NEI)
Information provided by (Responsible Party):
Krystel Huxlin, University of Rochester

Tracking Information
First Submitted Date  ICMJE October 13, 2021
First Posted Date  ICMJE October 28, 2021
Last Update Posted Date August 18, 2023
Actual Study Start Date  ICMJE September 26, 2003
Estimated Primary Completion Date October 15, 2031   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 27, 2021)
  • Direction Discrimination Threshold [ Time Frame: Baseline, 4-months, 12-months ]
    For each subject, the investigators will measure the change in ability to detect differences in the motion direction of visual stimuli relative to horizontal, measured in degrees of visual angle. These assessments will be based on what can be reliably detected at a 72-75% correct level of performance. These measures of change will be evaluated baseline and at each subsequent visit to the laboratory; minimally from baseline to 4-months, then baseline to 12-months from start of training.
  • Direction Integration Threshold [ Time Frame: Baseline to 4-months, 12-months ]
    This will measure the change in ability of subjects to integrate across a range of motion directions measured in degrees of visual angle. These assessments will be based on what range of motion directions can be reliably integrated at a 72-75% correct level of performance. These measures of change will be evaluated baseline and at each subsequent visit to the laboratory; minimally from baseline to 4-months, then baseline to 12-months from start of training.
  • Contrast Sensitivity for Direction [ Time Frame: Baseline, 4-months, 12-months ]
    Assessment of visual perception transfer to untrained psychophysical tasks of contrast sensitivity for direction discrimination. This is a change metric as transfer must be compared from pre- to post- each course of training. For each subject, the investigators will measure the ability to correctly detect the motion direction of visual stimuli that are also varying in contrast against a grey background. We will measure the luminance contrast that can be reliably detected at a 72-75% correct level of performance. These measures of change will be evaluated baseline and at each subsequent visit to the laboratory; minimally from baseline to 4-months, then baseline to 12-months from start of training.
  • Contrast Sensitivity for Static Orientation [ Time Frame: Baseline, 4-months, 12-months ]
    Assessment of visual perception transfer to untrained psychophysical tasks of contrast sensitivity for static orientation discrimination. This is a change metric as transfer must be compared from pre- to post- each course of training. For each subject, the investigators will measure the ability to correctly detect the orientation of non-moving visual stimuli that vary in contrast against a grey background. We will measure the luminance that can be reliably detected at a 72-75% correct level of performance. These measures of change will be evaluated baseline and at each subsequent visit to the laboratory; minimally from baseline to 4-months, then baseline to 12-months from start of training.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 27, 2021)
  • Humphrey 10-2 and 24-2 perimetry [ Time Frame: Baseline, 4-months, 12-months ]
    The investigators will measure the change in visual sensitivity (measured in decibels) at all locations tested by the system. These measures will be evaluated at baseline and at each subsequent visit to the laboratory; minimally from baseline to 4-months, then baseline to 12-months from start of training.
  • Goldmann perimetry [ Time Frame: Baseline, 4-months, 12-months ]
    The investigators will measure the change in area of vision (degrees squared) as encompassed by each isopter, measured by one of 3 different light stimuli. The 3 isopters which will be compared are: I2e 1asb, 0.25 mm^2 I4e 10asb, 0.25 mm^2 V4e 1000asb, 64 mm^2 These measures will be evaluated at baseline and at each subsequent visit to the laboratory; minimally from baseline to 4-months, then baseline to 12-months from start of training.
  • MAIA Visual Field Perimetry [ Time Frame: Baseline, 4-months, 12-months ]
    The investigators will measure the change in visual sensitivity (measured in decibels) at all locations tested by the system. These measures will be evaluated at baseline and at each subsequent visit to the laboratory; minimally from baseline to 4-months, then baseline to 12-months from start of training.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage
Official Title  ICMJE Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage
Brief Summary This project is intended to collect data using standard clinical tests and psychophysics to quantify the effect of visual cortical damage on the structure of the residual visual system, visual perception, spatial awareness, and brain function. The investigators will also assess the effect of intensive visual retraining on the residual visual system, processing of visual information and the use of such information in real-world situations following damage. This research is intended to improve our understanding of the consequences of permanent visual system damage in humans, of methods that can be used to reverse visual loss, and of brain mechanisms by which visual recovery is achieved.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Vision Loss Partial
  • Hemianopia
  • Hemianopia Homonymous
  • Quadrantanopia
  • Stroke, Ischemic
Intervention  ICMJE
  • Device: Training in the Blind Field
    A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
  • Device: Training in the Sighted Field
    This training will take place in lab at the University of Rochester Medical Center. Subject will perform one daily training session, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the visual field. The computer program will automatically create a record of patient performance during each training session. Subjects will train daily (about 30-40 minutes total), 5 to 7 days per week for at 7 - 14 days.
Study Arms  ICMJE
  • Experimental: Cortically Blind Subjects
    Intervention: Device: Training in the Blind Field
  • Placebo Comparator: Control
    Intervention: Device: Training in the Sighted Field
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: August 16, 2023)
280
Original Estimated Enrollment  ICMJE
 (submitted: October 27, 2021)
400
Estimated Study Completion Date  ICMJE October 15, 2031
Estimated Primary Completion Date October 15, 2031   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Cortically Blind Subject Inclusion Criteria:

  • Subjects between the ages of 17 and 75, who have sustained damage to primary visual cortex at age 17 or later, and are rendered blind over a portion of their visual field.
  • Subjects must have some intact visual cortical areas (other than primary visual cortex) in the damaged brain hemisphere. This assessment will be made from MRI or CT scans of the subject's head, which will be obtained via standard release from their neurologist.
  • Subjects who demonstrate a clear deficit in either simple or complex visual perception in portions of their visual field.
  • Subjects who are competent and responsible, as determined by the Principal Investigator.
  • Subjects who will receive retinal electrophysiology (mfERG) testing must have a report from their ophthalmologist stating that they are able to receive dilating drops

Cortically Blind Subject Exclusion Criteria:

  • Subjects who do not possess damage of primary visual cortex or its immediate afferents
  • Subjects who are suffering from an active disease process involving their nervous system.
  • Subjects who are unable to fixate visual targets precisely with their eyes
  • Subjects who have unreliable vision fields from prior testing indicated by greater than 20% fixation losses, false positives or false negatives
  • Best corrected visual acuity worse than 20/40 in either eye
  • Impaired foveal sensitivity as indicated by visual field tests
  • Presence of vision loss from ocular disease or disorder
  • Presence of bilateral visual acuity loss from any source
  • Subjects who are suffering from one-sided attentional neglect
  • Subjects who have impaired auditory thresholds that would influence test results and training efficacy (all our testing and training involves sound as a cue for trial/stimulus onset or as feedback)
  • Persons who lack the competence or are otherwise unable to perform the visual training exercises as directed.

Control Subject Inclusion Criteria:

  • Subjects must be between the ages of 17 and 75 years of age
  • Subjects must report no history of neurological disorder.
  • Subjects who are competent and responsible, as determined by the Principal Investigator.

Control Subject Exclusion criteria:

  • Subjects who possess damage to the visual system
  • Subjects who are suffering from an active disease process involving their nervous system.
  • Subjects who are unable to fixate visual targets precisely with their eyes
  • Best corrected visual acuity worse than 20/40 in either eye
  • Presence of vision loss from ocular disease or disorder
  • Presence of bilateral visual acuity loss from any source
  • Subjects who are suffering from one-sided attentional neglect
  • Subjects who have impaired auditory thresholds that would influence test results and training efficacy (all our testing and training involves sound as a cue for trial/stimulus onset or as feedback)
  • Persons who lack the competence or are otherwise unable to perform the visual testing/training exercises as directed.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 17 Years to 75 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05098236
Other Study ID Numbers  ICMJE STUDY00000075
R01EY027314 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Krystel Huxlin, University of Rochester
Original Responsible Party Same as current
Current Study Sponsor  ICMJE University of Rochester
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE National Eye Institute (NEI)
Investigators  ICMJE Not Provided
PRS Account University of Rochester
Verification Date August 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP